Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anthony Elias

Concepts (631)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
108
2024
2131
6.420
 Why?
Antineoplastic Combined Chemotherapy Protocols
95
2024
1558
3.850
 Why?
Sarcoma
32
2022
176
3.230
 Why?
Receptors, Estrogen
22
2021
424
2.390
 Why?
Triple Negative Breast Neoplasms
14
2024
191
2.360
 Why?
Receptor, ErbB-2
22
2024
325
2.110
 Why?
Hematopoietic Stem Cell Transplantation
36
2011
573
2.080
 Why?
Carcinoma, Small Cell
19
2003
168
1.770
 Why?
Soft Tissue Neoplasms
14
2022
112
1.630
 Why?
Carcinoma, Ductal, Breast
7
2018
82
1.540
 Why?
Neoadjuvant Therapy
17
2024
381
1.380
 Why?
Antineoplastic Agents
31
2023
2041
1.300
 Why?
Neoplasm Recurrence, Local
20
2022
955
1.250
 Why?
Neoplasm Staging
35
2024
1288
1.110
 Why?
Lung Neoplasms
38
2003
2327
1.080
 Why?
Receptors, Progesterone
13
2020
341
1.080
 Why?
Combined Modality Therapy
52
2024
1199
1.040
 Why?
Biomarkers, Tumor
17
2022
1175
1.030
 Why?
Paclitaxel
14
2024
213
0.950
 Why?
Mastectomy
9
2018
131
0.940
 Why?
Bone Marrow Transplantation
27
1998
269
0.930
 Why?
Bone Neoplasms
7
2025
229
0.880
 Why?
Doxorubicin
23
2024
322
0.840
 Why?
Antineoplastic Agents, Alkylating
5
2018
69
0.770
 Why?
Female
167
2025
68017
0.750
 Why?
Receptors, Androgen
7
2018
143
0.750
 Why?
Disease-Free Survival
24
2023
647
0.740
 Why?
Antibodies, Monoclonal, Humanized
9
2024
754
0.710
 Why?
Humans
222
2025
128020
0.710
 Why?
Antineoplastic Agents, Hormonal
10
2018
158
0.690
 Why?
Maytansine
3
2021
16
0.680
 Why?
Liposarcoma
4
2023
27
0.670
 Why?
Middle Aged
110
2025
30813
0.670
 Why?
Neoplasm Metastasis
23
2024
608
0.620
 Why?
Chemotherapy, Adjuvant
23
2023
377
0.610
 Why?
Dioxoles
2
2015
9
0.580
 Why?
Tetrahydroisoquinolines
2
2015
8
0.580
 Why?
Cyclophosphamide
31
2024
227
0.580
 Why?
Adult
111
2025
35177
0.580
 Why?
Ifosfamide
19
1998
34
0.530
 Why?
Androgen Receptor Antagonists
6
2021
36
0.530
 Why?
Phenylthiohydantoin
5
2017
44
0.530
 Why?
Dasatinib
1
2016
51
0.520
 Why?
Trastuzumab
10
2024
100
0.510
 Why?
Treatment Outcome
43
2024
10110
0.500
 Why?
Neoplasms, Hormone-Dependent
3
2012
38
0.500
 Why?
Aged
63
2025
21892
0.490
 Why?
Estrogen Receptor alpha
5
2021
132
0.470
 Why?
Drug Administration Schedule
24
2018
755
0.470
 Why?
Carboplatin
21
2016
140
0.460
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
72
0.460
 Why?
Carcinoma, Non-Small-Cell Lung
17
2001
1045
0.450
 Why?
Clinical Trials as Topic
19
2018
997
0.440
 Why?
Estrogens
6
2018
342
0.420
 Why?
Dacarbazine
9
2018
94
0.400
 Why?
Neoplasms
20
2009
2460
0.390
 Why?
Survival Rate
19
2021
1870
0.380
 Why?
Tamoxifen
9
2018
200
0.380
 Why?
Survival Analysis
23
2010
1262
0.370
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
940
0.360
 Why?
Pyrimidines
3
2020
446
0.360
 Why?
Antibodies, Monoclonal
9
2024
1354
0.350
 Why?
Neoplasms, Second Primary
3
2022
106
0.350
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
54
0.350
 Why?
Dose-Response Relationship, Drug
17
2017
1943
0.350
 Why?
Prognosis
21
2021
3766
0.350
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
8
1999
146
0.340
 Why?
Taxoids
7
2023
95
0.340
 Why?
Remission Induction
16
2002
267
0.330
 Why?
Breast Neoplasms, Male
3
2018
29
0.330
 Why?
Drug Resistance, Neoplasm
7
2017
744
0.320
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1343
0.310
 Why?
Neoplastic Cells, Circulating
2
2020
70
0.300
 Why?
Mesna
12
1998
15
0.290
 Why?
Sarcoma, Ewing
3
2022
87
0.280
 Why?
Leiomyosarcoma
2
2018
27
0.270
 Why?
Cisplatin
14
2000
297
0.270
 Why?
Immunoconjugates
3
2024
101
0.270
 Why?
Sternum
1
2006
25
0.260
 Why?
Tumor Microenvironment
4
2024
620
0.260
 Why?
Immunohistochemistry
5
2016
1663
0.260
 Why?
Mastectomy, Segmental
2
2009
85
0.250
 Why?
Pyridines
2
2025
474
0.250
 Why?
Chondrosarcoma
1
2025
15
0.240
 Why?
Peripheral Blood Stem Cell Transplantation
2
2002
21
0.240
 Why?
Carcinoma, Ductal
1
2005
11
0.240
 Why?
Transplantation, Autologous
19
2002
211
0.240
 Why?
Melphalan
10
2002
29
0.240
 Why?
Isocitrate Dehydrogenase
1
2025
51
0.240
 Why?
Protein Kinase Inhibitors
4
2019
875
0.230
 Why?
Lymph Nodes
1
2007
465
0.230
 Why?
Cell Adhesion Molecules
2
2021
173
0.230
 Why?
Carcinoma
2
2008
215
0.230
 Why?
Glycine
1
2025
163
0.230
 Why?
Risk Reduction Behavior
2
2016
208
0.230
 Why?
Ovarian Neoplasms
3
2022
487
0.220
 Why?
Drug Evaluation
19
1998
80
0.220
 Why?
Adjuvants, Immunologic
3
2022
221
0.220
 Why?
Deoxycytidine
4
2020
163
0.220
 Why?
Survivors
3
2016
462
0.220
 Why?
Ribonuclease III
2
2016
37
0.210
 Why?
Hodgkin Disease
4
2016
134
0.210
 Why?
Thiotepa
13
2002
20
0.210
 Why?
Behavior Therapy
2
2016
236
0.210
 Why?
Weight Loss
4
2016
725
0.210
 Why?
Alkylating Agents
3
2000
23
0.210
 Why?
DEAD-box RNA Helicases
2
2016
65
0.210
 Why?
Male
65
2025
62758
0.210
 Why?
Triazoles
2
2022
150
0.200
 Why?
Gene Expression Profiling
6
2017
1681
0.200
 Why?
Medical Oncology
5
2024
271
0.200
 Why?
Disease Management
5
2020
583
0.200
 Why?
Employment
1
2024
165
0.200
 Why?
Mutation
4
2025
3682
0.200
 Why?
Obesity
4
2018
2859
0.200
 Why?
Overweight
3
2016
522
0.200
 Why?
Aged, 80 and over
13
2021
7029
0.200
 Why?
Salvage Therapy
6
2010
133
0.190
 Why?
Circulating Tumor DNA
1
2022
28
0.190
 Why?
Hydrazines
1
2022
34
0.190
 Why?
Referral and Consultation
1
2007
724
0.190
 Why?
Carcinoma in Situ
2
2012
45
0.190
 Why?
Etoposide
10
2001
148
0.190
 Why?
Emergency Medicine
1
2024
215
0.190
 Why?
Tumor Cells, Cultured
9
2020
930
0.190
 Why?
Hematologic Diseases
6
2008
60
0.190
 Why?
Sarcoma, Synovial
1
2021
16
0.190
 Why?
Liposarcoma, Myxoid
1
2021
9
0.190
 Why?
Aromatase Inhibitors
4
2021
51
0.180
 Why?
Recombinant Fusion Proteins
1
2024
634
0.180
 Why?
Endpoint Determination
1
2021
75
0.180
 Why?
Time Factors
12
2020
6479
0.170
 Why?
Sentinel Lymph Node Biopsy
3
2017
107
0.170
 Why?
Cancer Care Facilities
1
2020
32
0.170
 Why?
Hematopoietic Stem Cells
5
1996
379
0.170
 Why?
Indazoles
1
2020
65
0.170
 Why?
Leukocytes, Mononuclear
3
2020
539
0.170
 Why?
Cell Separation
3
2017
312
0.170
 Why?
Diphosphonates
1
2020
56
0.170
 Why?
Pyrroles
2
2013
189
0.170
 Why?
Diet
3
2018
1198
0.160
 Why?
Bone Marrow
8
2000
267
0.160
 Why?
Cell Line, Tumor
9
2017
3168
0.160
 Why?
Antigens, Neoplasm
4
2021
308
0.160
 Why?
Proportional Hazards Models
6
2020
1194
0.160
 Why?
MCF-7 Cells
5
2017
115
0.150
 Why?
Fluorouracil
7
2013
197
0.150
 Why?
CA-125 Antigen
2
2013
15
0.150
 Why?
Nitriles
5
2017
159
0.150
 Why?
Epithelial-Mesenchymal Transition
1
2020
201
0.150
 Why?
Benzamides
5
2017
195
0.150
 Why?
Bayes Theorem
4
2024
369
0.150
 Why?
Research Design
3
2021
1034
0.150
 Why?
Cyclin-Dependent Kinase 4
1
2018
41
0.150
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
52
0.150
 Why?
Programmed Cell Death 1 Receptor
1
2020
226
0.150
 Why?
Cell Cycle
1
2021
580
0.150
 Why?
Indoles
2
2013
371
0.150
 Why?
Cyclin-Dependent Kinase 6
1
2018
38
0.150
 Why?
Infusions, Intravenous
10
2020
390
0.140
 Why?
Kaplan-Meier Estimate
6
2018
851
0.140
 Why?
Fibromatosis, Aggressive
1
2017
17
0.140
 Why?
Tetrahydronaphthalenes
1
2017
29
0.140
 Why?
Vaccines
1
2022
394
0.140
 Why?
Microbubbles
1
2017
48
0.140
 Why?
Valine
1
2017
80
0.140
 Why?
Camptothecin
3
2024
106
0.140
 Why?
Internship and Residency
2
2024
1043
0.140
 Why?
Immunotherapy
2
2018
586
0.140
 Why?
Lymph Node Excision
3
2015
164
0.140
 Why?
Amyloid Precursor Protein Secretases
1
2017
80
0.140
 Why?
Sulfonamides
1
2020
494
0.130
 Why?
Axilla
3
2017
45
0.130
 Why?
Androgen Antagonists
2
2015
79
0.130
 Why?
Cancer-Associated Fibroblasts
1
2016
13
0.130
 Why?
Gonadal Steroid Hormones
1
2018
129
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
71
0.130
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
67
0.130
 Why?
Hematopoietic Cell Growth Factors
2
1995
4
0.130
 Why?
Follow-Up Studies
6
2025
4853
0.130
 Why?
Ultrasonography, Mammary
1
2016
12
0.130
 Why?
Lymphatic Metastasis
3
2017
317
0.130
 Why?
Thiazoles
1
2016
115
0.130
 Why?
Antibody Specificity
1
2016
182
0.130
 Why?
Tumor Suppressor Protein p53
2
2023
504
0.130
 Why?
Neoplasm Invasiveness
3
2016
477
0.130
 Why?
Maximum Tolerated Dose
1
2016
192
0.120
 Why?
Antibiotics, Antineoplastic
1
2016
120
0.120
 Why?
Neoplastic Stem Cells
2
2017
377
0.120
 Why?
Quinolines
1
2016
154
0.120
 Why?
Benzimidazoles
1
2016
158
0.120
 Why?
Pyrazoles
1
2018
401
0.120
 Why?
Recurrence
5
2020
993
0.120
 Why?
Drug Therapy, Combination
4
2014
1012
0.120
 Why?
Disease Progression
7
2018
2598
0.120
 Why?
Mammography
1
2016
146
0.120
 Why?
Radiotherapy, Adjuvant
5
2016
209
0.110
 Why?
Administration, Oral
4
2020
766
0.110
 Why?
Homeodomain Proteins
2
2018
489
0.110
 Why?
Young Adult
10
2025
12282
0.110
 Why?
TOR Serine-Threonine Kinases
1
2017
380
0.110
 Why?
Antibodies
1
2016
392
0.110
 Why?
Animals
16
2021
34487
0.110
 Why?
Societies, Medical
1
2018
741
0.110
 Why?
Exercise
2
2015
1917
0.110
 Why?
Brain Edema
1
2014
60
0.110
 Why?
Hepatic Veno-Occlusive Disease
3
2002
14
0.110
 Why?
Radiotherapy Dosage
3
1999
250
0.110
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
90
0.110
 Why?
Comorbidity
5
2017
1537
0.110
 Why?
Vascular Neoplasms
1
2013
17
0.110
 Why?
Mice
12
2021
16574
0.110
 Why?
Radiotherapy
3
2015
185
0.110
 Why?
Testicular Neoplasms
1
1995
102
0.110
 Why?
Clinical Trials, Phase I as Topic
3
2024
50
0.110
 Why?
Epigenesis, Genetic
2
2018
614
0.110
 Why?
Adenocarcinoma
6
2015
888
0.110
 Why?
Cellular Reprogramming
1
2014
94
0.100
 Why?
Keratins
2
2017
175
0.100
 Why?
Bridged-Ring Compounds
3
2020
12
0.100
 Why?
Mercaptoethanol
2
1990
11
0.100
 Why?
Patient Selection
4
2016
658
0.100
 Why?
Apoptosis
6
2023
2425
0.100
 Why?
Cell Proliferation
6
2017
2337
0.100
 Why?
Gallium Radioisotopes
1
1992
14
0.100
 Why?
Bone Marrow Cells
4
2000
293
0.100
 Why?
Chromatin
1
2016
477
0.100
 Why?
Adolescent
23
2025
20158
0.100
 Why?
Carmustine
10
2001
50
0.100
 Why?
Protein-Tyrosine Kinases
2
2022
430
0.100
 Why?
Lymphoma, Non-Hodgkin
3
2001
76
0.100
 Why?
Retrospective Studies
12
2023
14404
0.100
 Why?
Anthracyclines
3
2023
46
0.100
 Why?
Brain Neoplasms
5
2014
1163
0.100
 Why?
Methotrexate
4
2002
249
0.090
 Why?
Liver Neoplasms
3
2015
633
0.090
 Why?
Weight Reduction Programs
1
2012
111
0.090
 Why?
Neoplasm, Residual
2
2022
119
0.090
 Why?
Radiosurgery
1
2014
318
0.090
 Why?
RNA, Catalytic
1
2012
185
0.090
 Why?
Polydeoxyribonucleotides
2
2002
13
0.090
 Why?
Aorta
1
2013
408
0.090
 Why?
Neutropenia
5
2013
134
0.090
 Why?
Neoplasm Grading
3
2017
283
0.090
 Why?
Carcinoma, Lobular
1
2011
48
0.090
 Why?
Leukapheresis
4
2001
21
0.090
 Why?
Multivariate Analysis
4
2013
1492
0.090
 Why?
Angiogenesis Inhibitors
1
2012
215
0.080
 Why?
Keratin-5
1
2010
49
0.080
 Why?
Biopsy
3
2018
1077
0.080
 Why?
Molecular Targeted Therapy
3
2018
384
0.080
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
97
0.080
 Why?
Peptide Mapping
1
2010
61
0.080
 Why?
Databases, Protein
1
2010
62
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
136
0.080
 Why?
Urinary Tract
1
1990
38
0.080
 Why?
Postmenopause
2
2017
348
0.080
 Why?
Benzenesulfonates
1
2009
18
0.080
 Why?
CD146 Antigen
2
2021
41
0.080
 Why?
BRCA2 Protein
1
2009
53
0.080
 Why?
Health Facilities
1
2009
79
0.080
 Why?
Thrombophilia
1
2009
66
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
52
0.080
 Why?
Observer Variation
1
2010
310
0.080
 Why?
Patient Care
1
2009
108
0.080
 Why?
United States
9
2023
13785
0.080
 Why?
Fibrinolytic Agents
2
2002
248
0.070
 Why?
Perimenopause
1
2008
60
0.070
 Why?
Mice, Nude
3
2017
675
0.070
 Why?
Randomized Controlled Trials as Topic
6
2000
1356
0.070
 Why?
Fatigue
3
2018
316
0.070
 Why?
Xenograft Model Antitumor Assays
3
2017
809
0.070
 Why?
In Situ Hybridization
2
2010
291
0.070
 Why?
Bone Marrow Diseases
4
2000
19
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
313
0.070
 Why?
Blotting, Western
1
2010
1169
0.070
 Why?
Risk Assessment
2
2020
3223
0.070
 Why?
Reproducibility of Results
2
2016
3009
0.070
 Why?
Pneumonectomy
3
1997
151
0.070
 Why?
Sputum
1
1988
301
0.070
 Why?
Quality of Life
2
2015
2672
0.070
 Why?
Clinical Decision-Making
2
2020
302
0.060
 Why?
Risk Factors
7
2020
9696
0.060
 Why?
Neoplasm Proteins
2
2007
419
0.060
 Why?
Life Tables
2
2002
18
0.060
 Why?
Anilides
2
2016
73
0.060
 Why?
Positron-Emission Tomography
1
2006
283
0.060
 Why?
New Jersey
1
2024
12
0.060
 Why?
Predictive Value of Tests
2
2016
1934
0.060
 Why?
Colony-Stimulating Factors
3
1988
35
0.060
 Why?
Enzyme Inhibitors
1
2008
809
0.060
 Why?
Receptor, TIE-2
1
2024
12
0.060
 Why?
Granulocytes
4
1995
79
0.060
 Why?
Genes, Neoplasm
1
2004
20
0.060
 Why?
New York
1
2024
124
0.060
 Why?
Ricin
2
1997
8
0.060
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
755
0.060
 Why?
Growth Substances
3
1988
150
0.060
 Why?
Magnetic Resonance Imaging
1
2016
3371
0.060
 Why?
MicroRNAs
1
2010
674
0.060
 Why?
Forecasting
3
2000
355
0.060
 Why?
Patient Care Planning
1
2005
148
0.060
 Why?
Thrombocytopenia
3
2013
184
0.050
 Why?
Mammaplasty
2
2016
98
0.050
 Why?
Signal Transduction
5
2018
4812
0.050
 Why?
Up-Regulation
2
2017
822
0.050
 Why?
Activating Transcription Factor 4
1
2023
20
0.050
 Why?
Proteasome Inhibitors
1
2023
42
0.050
 Why?
Proteomics
1
2010
1008
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
63
0.050
 Why?
Transcriptome
2
2023
879
0.050
 Why?
Cyclin E
1
2022
23
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
3
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
92
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
145
0.050
 Why?
Treatment Failure
2
2001
338
0.050
 Why?
Oncogene Proteins
1
2022
52
0.050
 Why?
Luminescent Measurements
1
2003
78
0.050
 Why?
Ribose
1
2022
21
0.050
 Why?
Blood Transfusion, Autologous
2
1993
16
0.050
 Why?
Carbolines
1
2022
27
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
19
0.050
 Why?
Career Choice
1
2024
207
0.050
 Why?
Adenosine Diphosphate
1
2022
78
0.050
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
81
0.050
 Why?
Tomography, X-Ray Computed
2
2015
2509
0.050
 Why?
Oncogenes
1
2022
109
0.050
 Why?
Actuarial Analysis
2
1993
25
0.050
 Why?
Cell Division
2
2001
777
0.050
 Why?
Colony-Forming Units Assay
4
1996
90
0.050
 Why?
Gene Expression
2
2020
1454
0.050
 Why?
Carcinoembryonic Antigen
1
2001
41
0.050
 Why?
Phthalazines
1
2021
40
0.040
 Why?
Fellowships and Scholarships
1
2024
271
0.040
 Why?
Prospective Studies
5
2022
7035
0.040
 Why?
Age Factors
3
2018
3100
0.040
 Why?
Longitudinal Studies
2
2012
2706
0.040
 Why?
Clodronic Acid
1
2020
12
0.040
 Why?
Transplantation Immunology
1
2000
33
0.040
 Why?
Estradiol
2
2016
486
0.040
 Why?
Extracellular Matrix
1
2024
495
0.040
 Why?
Progesterone
1
2002
242
0.040
 Why?
Ligands
1
2022
616
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
356
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
16
0.040
 Why?
Thoracotomy
2
1997
74
0.040
 Why?
Polymerase Chain Reaction
1
2003
1020
0.040
 Why?
Leucovorin
2
1997
68
0.040
 Why?
Bone Density Conservation Agents
1
2020
71
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
22
0.040
 Why?
Dendritic Cells
2
2000
475
0.040
 Why?
Mechlorethamine
1
2000
56
0.040
 Why?
Myelodysplastic Syndromes
1
2001
128
0.040
 Why?
Drug Resistance
1
1999
165
0.040
 Why?
Child
8
2022
20636
0.040
 Why?
Neoplasms, Experimental
1
2000
169
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
31
0.040
 Why?
Cell Cycle Proteins
1
2022
578
0.040
 Why?
Receptors, Steroid
1
2019
49
0.040
 Why?
Cluster Analysis
2
2012
477
0.040
 Why?
Piperazines
1
2021
332
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Leukemia
1
2001
228
0.040
 Why?
Loss of Function Mutation
1
2018
39
0.040
 Why?
Enterocolitis, Pseudomembranous
1
1998
27
0.040
 Why?
Cross-Over Studies
1
2020
507
0.040
 Why?
Expectorants
1
1998
24
0.040
 Why?
Aurora Kinase A
1
2018
55
0.040
 Why?
Nervous System
2
1997
66
0.040
 Why?
Retreatment
1
2018
69
0.040
 Why?
Statistics, Nonparametric
1
1999
419
0.040
 Why?
Mediastinum
1
1998
23
0.040
 Why?
Disease Susceptibility
1
2020
331
0.040
 Why?
Nausea
1
2018
108
0.040
 Why?
Epithelial Cell Adhesion Molecule
1
2017
10
0.040
 Why?
Administration, Intravenous
1
2018
137
0.040
 Why?
Watchful Waiting
1
2018
65
0.040
 Why?
Extremities
2
1989
128
0.040
 Why?
SEER Program
1
2018
206
0.040
 Why?
Breast
1
2018
152
0.040
 Why?
Medicare
1
2023
715
0.040
 Why?
Double-Blind Method
1
2022
1852
0.030
 Why?
Diarrhea
1
2018
178
0.030
 Why?
Cell Hypoxia
1
1998
228
0.030
 Why?
Everolimus
1
2017
59
0.030
 Why?
Thorax
1
1997
41
0.030
 Why?
Random Allocation
2
1988
342
0.030
 Why?
Cohort Studies
4
2001
5378
0.030
 Why?
Phosphoramide Mustards
1
2016
1
0.030
 Why?
Heterografts
1
2017
128
0.030
 Why?
Proto-Oncogene Proteins c-akt
1
2019
419
0.030
 Why?
Immunotoxins
1
1997
54
0.030
 Why?
Cyclohexanes
1
2016
21
0.030
 Why?
Cell Survival
1
2000
1073
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
65
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
112
0.030
 Why?
Placebos
1
2016
201
0.030
 Why?
Gene Knockdown Techniques
1
2017
311
0.030
 Why?
Carcinogenesis
1
2018
209
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
175
0.030
 Why?
Injections, Intravenous
2
1993
197
0.030
 Why?
Blood Specimen Collection
1
1995
33
0.030
 Why?
Fertility Preservation
1
2016
53
0.030
 Why?
Organoplatinum Compounds
3
1990
40
0.030
 Why?
Antidotes
1
1997
136
0.030
 Why?
Mortality
1
1997
306
0.030
 Why?
Blood Component Transfusion
2
1994
79
0.030
 Why?
Transcriptional Activation
1
2017
355
0.030
 Why?
Genetic Therapy
1
1997
290
0.030
 Why?
Digestive System
1
1995
29
0.030
 Why?
Kidney
2
1995
1306
0.030
 Why?
Vincristine
1
1995
109
0.030
 Why?
Fertility
1
2016
159
0.030
 Why?
Interleukin-3
1
1994
24
0.030
 Why?
Hormones
1
2015
140
0.030
 Why?
Weight Gain
1
2018
503
0.030
 Why?
Child, Preschool
6
2013
10378
0.030
 Why?
Pulmonary Fibrosis
3
1993
377
0.030
 Why?
Bacterial Infections
1
1996
232
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
251
0.030
 Why?
Adipose Tissue
1
2018
589
0.030
 Why?
Odds Ratio
1
2017
1018
0.030
 Why?
Leukocyte Count
5
1996
325
0.030
 Why?
Tosyl Compounds
1
2014
16
0.030
 Why?
Drug Discovery
1
2015
130
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Protein Transport
1
2015
420
0.030
 Why?
HEK293 Cells
1
2016
681
0.030
 Why?
Capecitabine
1
2013
46
0.030
 Why?
Transplantation, Heterologous
1
2014
187
0.030
 Why?
Necrosis
1
2014
228
0.030
 Why?
Neoplasm Transplantation
1
2014
257
0.030
 Why?
Cell Nucleus
1
2016
579
0.030
 Why?
Alternative Splicing
1
2015
216
0.030
 Why?
Cross-Sectional Studies
1
2024
5034
0.030
 Why?
Erythropoietin
1
1994
84
0.030
 Why?
Binding Sites
1
2016
1241
0.030
 Why?
Gene Silencing
1
2014
183
0.030
 Why?
Blood Cells
1
1993
38
0.030
 Why?
Nutritional Status
1
2015
326
0.030
 Why?
Sensitivity and Specificity
2
2000
1813
0.030
 Why?
Recombinant Proteins
5
1997
1286
0.030
 Why?
Anemia
1
1994
160
0.030
 Why?
CD24 Antigen
1
2012
20
0.030
 Why?
Energy Intake
1
2015
454
0.020
 Why?
Radionuclide Imaging
1
1992
121
0.020
 Why?
Diet, Reducing
1
2012
86
0.020
 Why?
Psychotherapy, Group
1
2012
64
0.020
 Why?
Models, Biological
1
1999
1689
0.020
 Why?
Hyaluronan Receptors
1
2012
97
0.020
 Why?
Counseling
1
2015
382
0.020
 Why?
Antigens, CD34
3
1996
89
0.020
 Why?
Surveys and Questionnaires
1
2024
5353
0.020
 Why?
Feasibility Studies
4
1998
860
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
66
0.020
 Why?
Mice, SCID
1
2012
350
0.020
 Why?
Tumor Burden
1
2012
283
0.020
 Why?
Fluorescent Antibody Technique
2
1990
370
0.020
 Why?
Disease Models, Animal
1
2021
3936
0.020
 Why?
Logistic Models
1
2016
1975
0.020
 Why?
Biopsy, Needle
1
2011
187
0.020
 Why?
Mice, Inbred NOD
1
2012
586
0.020
 Why?
Colorado
1
2020
4369
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
39
0.020
 Why?
Blast Crisis
1
1990
33
0.020
 Why?
Bilirubin
2
2002
92
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
41
0.020
 Why?
Health Status
1
2015
747
0.020
 Why?
Immunoblotting
1
2010
301
0.020
 Why?
Pemetrexed
1
2010
32
0.020
 Why?
Kidney Diseases
2
1991
370
0.020
 Why?
Gene Regulatory Networks
1
2012
279
0.020
 Why?
Glutamates
1
2010
56
0.020
 Why?
Graft Survival
1
1993
503
0.020
 Why?
Cytokines
1
1998
1984
0.020
 Why?
Magnetics
1
1990
44
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
57
0.020
 Why?
Guanine
1
2010
76
0.020
 Why?
Multiple Organ Failure
2
2002
122
0.020
 Why?
Urologic Diseases
1
1990
38
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
323
0.020
 Why?
Health Behavior
1
2015
740
0.020
 Why?
Microspheres
1
1990
125
0.020
 Why?
Chromosome Aberrations
1
1990
148
0.020
 Why?
Spinal Cord Neoplasms
1
1989
38
0.020
 Why?
Blood
1
1990
99
0.020
 Why?
Promoter Regions, Genetic
1
2014
1198
0.020
 Why?
Cell Movement
1
2014
933
0.020
 Why?
Clone Cells
1
1990
255
0.020
 Why?
Pregnancy Trimester, Second
1
2009
77
0.020
 Why?
Lymphoma
1
1990
194
0.020
 Why?
Hypertension
1
2018
1234
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
112
0.020
 Why?
Central Nervous System Diseases
1
1990
67
0.020
 Why?
Hematuria
1
1989
12
0.020
 Why?
Vinblastine
2
2001
68
0.020
 Why?
DNA Methylation
1
2014
604
0.020
 Why?
Creatinine
1
1991
478
0.020
 Why?
False Negative Reactions
1
1988
50
0.020
 Why?
Pregnancy Trimester, First
1
2009
138
0.020
 Why?
Histones
1
2014
585
0.020
 Why?
Niacinamide
1
2009
73
0.020
 Why?
Leukopenia
1
1988
27
0.020
 Why?
Immunophenotyping
2
2000
309
0.020
 Why?
Phenylurea Compounds
1
2009
89
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
181
0.020
 Why?
False Positive Reactions
1
1988
113
0.020
 Why?
Exercise Therapy
1
2012
412
0.020
 Why?
Macrophages
2
1995
1460
0.020
 Why?
Electrophoresis
1
1988
30
0.020
 Why?
Drug Interactions
1
1990
361
0.020
 Why?
Transfection
1
2010
891
0.020
 Why?
Antigens, Differentiation
1
1988
82
0.020
 Why?
Hospitals, Veterans
1
2009
255
0.020
 Why?
Perilipin-1
1
2008
16
0.020
 Why?
Estrogen Receptor Modulators
1
2008
17
0.020
 Why?
Staining and Labeling
1
1988
137
0.020
 Why?
S100 Proteins
1
2008
36
0.020
 Why?
Antigens, Surface
1
1988
150
0.020
 Why?
Vimentin
1
1988
50
0.020
 Why?
Nervous System Diseases
1
1991
251
0.020
 Why?
Community Health Services
1
2009
226
0.020
 Why?
Androstadienes
1
2008
106
0.020
 Why?
Central Nervous System
1
1990
254
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2261
0.020
 Why?
Sarcoma, Kaposi
1
1988
76
0.020
 Why?
Lung Diseases
2
1992
713
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Biomarkers
1
2018
3874
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1272
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
72
0.020
 Why?
Academic Medical Centers
1
2009
478
0.020
 Why?
Risk
2
2000
850
0.020
 Why?
Heart Diseases
1
1990
345
0.020
 Why?
Gastrointestinal Diseases
1
2008
196
0.020
 Why?
Stem Cell Transplantation
1
2007
165
0.020
 Why?
Phosphoproteins
1
2008
328
0.020
 Why?
Immunoglobulin G
1
1990
842
0.020
 Why?
Bevacizumab
1
2006
129
0.020
 Why?
Quality of Health Care
1
2009
605
0.010
 Why?
Body Mass Index
1
2012
2260
0.010
 Why?
Melanoma
2
1988
722
0.010
 Why?
Carrier Proteins
1
2008
730
0.010
 Why?
Ascites
1
2002
44
0.010
 Why?
Brain
1
2014
2615
0.010
 Why?
Cells, Cultured
1
1990
4006
0.010
 Why?
Phenotype
1
2010
3039
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
13
0.010
 Why?
Hemorrhage
2
1998
643
0.010
 Why?
Carcinoma, Large Cell
1
2001
15
0.010
 Why?
Transplantation Conditioning
1
2002
165
0.010
 Why?
Phytohemagglutinins
1
2000
28
0.010
 Why?
CD4-CD8 Ratio
1
2000
22
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
48
0.010
 Why?
Hypersensitivity, Delayed
1
2000
28
0.010
 Why?
Drug Synergism
1
2001
356
0.010
 Why?
Microcomputers
1
2000
16
0.010
 Why?
Graft vs Host Disease
1
2002
238
0.010
 Why?
Skin Tests
1
2000
100
0.010
 Why?
France
1
2000
29
0.010
 Why?
Louisiana
1
2000
27
0.010
 Why?
Philadelphia
1
2000
45
0.010
 Why?
Immunoglobulins
1
2000
157
0.010
 Why?
Automation
1
2000
79
0.010
 Why?
Immunity
1
2000
132
0.010
 Why?
Lung
1
1992
3745
0.010
 Why?
Personnel Selection
1
1980
72
0.010
 Why?
Marriage
1
1980
113
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
87
0.010
 Why?
Heart Failure
1
1992
2141
0.010
 Why?
Thalassemia
1
1998
6
0.010
 Why?
Interleukin-4
1
1999
212
0.010
 Why?
Multicenter Studies as Topic
1
2000
285
0.010
 Why?
Receptors, Purinergic P1
1
1998
23
0.010
 Why?
Pilot Projects
2
1994
1559
0.010
 Why?
Reference Values
1
2000
776
0.010
 Why?
Microscopy, Fluorescence
1
2000
399
0.010
 Why?
Infant, Newborn
1
2009
5688
0.010
 Why?
Acute Disease
1
2001
961
0.010
 Why?
Filgrastim
1
1997
7
0.010
 Why?
Killer Cells, Natural
1
2000
426
0.010
 Why?
Adenoviruses, Human
1
1996
26
0.010
 Why?
Pregnancy
1
2009
6355
0.010
 Why?
Heparin
1
1998
246
0.010
 Why?
Lymphoma, B-Cell
1
1998
105
0.010
 Why?
Tissue Plasminogen Activator
1
1998
219
0.010
 Why?
Freezing
1
1996
86
0.010
 Why?
Lymphocyte Activation
1
2000
1096
0.010
 Why?
Lymphocyte Depletion
1
1996
129
0.010
 Why?
Genes, Reporter
1
1996
265
0.010
 Why?
Carcinoma, Squamous Cell
1
2001
620
0.010
 Why?
Drug Tolerance
1
1995
83
0.010
 Why?
Reticulocyte Count
1
1994
6
0.010
 Why?
Kidney Function Tests
1
1995
145
0.010
 Why?
Topotecan
1
1994
12
0.010
 Why?
Incidence
1
2001
2614
0.010
 Why?
Antigens, CD
1
1996
481
0.010
 Why?
Registries
1
2002
1873
0.010
 Why?
Liver
1
2002
1826
0.010
 Why?
Glioblastoma
1
1996
323
0.010
 Why?
Urinary Bladder Diseases
1
1993
18
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
488
0.010
 Why?
Heart
1
1997
637
0.010
 Why?
Flow Cytometry
1
1996
1140
0.010
 Why?
Boston
1
1993
86
0.010
 Why?
Iron
1
1994
282
0.010
 Why?
Palliative Care
1
1998
714
0.010
 Why?
Cell Line
1
1996
2736
0.010
 Why?
Immunologic Factors
1
1993
227
0.010
 Why?
Cystitis
1
1990
22
0.010
 Why?
Metabolic Clearance Rate
1
1989
108
0.000
 Why?
Introns
1
1990
249
0.000
 Why?
Prostatic Neoplasms
1
1996
1011
0.000
 Why?
Platinum
1
1989
44
0.000
 Why?
Drug Combinations
1
1990
323
0.000
 Why?
Brain Diseases
1
1990
136
0.000
 Why?
Macrophage-1 Antigen
1
1988
28
0.000
 Why?
Infant
1
2002
8912
0.000
 Why?
Bone Marrow Examination
1
1988
6
0.000
 Why?
Platelet Count
1
1988
82
0.000
 Why?
Erythrocyte Count
1
1988
20
0.000
 Why?
Methods
1
1988
64
0.000
 Why?
Pelvic Neoplasms
1
1988
19
0.000
 Why?
Erythroblasts
1
1988
15
0.000
 Why?
DNA Damage
1
1990
363
0.000
 Why?
Acute Kidney Injury
1
1995
777
0.000
 Why?
Fever
1
1988
295
0.000
 Why?
In Vitro Techniques
1
1988
1047
0.000
 Why?
Pneumonia
1
1992
600
0.000
 Why?
Statistics as Topic
1
1987
303
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (631) concept(s)
_
Co-Authors Expand Description
See all (61) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)